Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.